The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Introduction:Chronic graft-versus host disease (GVHD) is a serious complication that develops in 35-50% of patients in the late period after allogeneic hematopoetic stem cell transplantation. About half of the patients are resistant to corticosteroids, which is the first-line treatment of chronic GV...

Full description

Bibliographic Details
Main Authors:	Ahmet Sarıcı, Mehmet Ali Erkurt, İrfan Kuku, Emin Kaya, İlhami Berber, Soykan Biçim, Emine Hidayet, Ahmet Kaya, Ömer Faruk Bahçecioğlu, Lokman Hekim Tanrıverdi, Sıdıka Gülkan Özkan
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2023-05-01
Series:	İstanbul Medical Journal
Subjects:	steroid-resistant graft-versus host disease ibrutinib corticosteroids allo-hsct chronic gvhd
Online Access:	http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/the-experience-of-brutinib-in-chronic-graft-versus/60513

Similar Items

Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020-02-01)

Analysis of Correlation between Body Mass Index and the Incidence of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
by: Masoud Soleimani, et al.
Published: (2021-09-01)

Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation
by: Xiaoyu Zhang, et al.
Published: (2022-12-01)

T-Cell Metabolism in Graft Versus Host Disease
by: Franziska Karl, et al.
Published: (2021-10-01)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
by: Lv Meng, et al.
Published: (2012-03-01)

Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS in vitro and correlates with inflammatory parameters and clinical severity
by: Bernardo López-Andrade, et al.
Published: (2024-03-01)

IMPACT OF HLA-DPB1 INCOMPATIBILITY ON THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM HLA-A-B-C–DRB1-DQB1-COMPATIBLE UNRELATED DONOR
by: E. G. Khamaganova, et al.
Published: (2018-05-01)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
by: Nancy Y. Villa, et al.
Published: (2016-03-01)

BK virus incidence, risk factors and its effect on mortality in hematopoietic stem cell transplant patients-single center experience
by: Mehmet Veysi Deviren, et al.
Published: (2021-09-01)

The frequency of HLA A, B, C, DP, DQ, DR allele in patients of Turkish and Syrian nationals with allogeneic stem cell transplantation
by: Ahmet Kaya, et al.
Published: (2022-01-01)

Convalescent plasma therapy in COVID-19
by: Ayse Uysal, et al.
Published: (2022-06-01)

Etiological evaluation and the role of plasma exchange treatment in trombotic microangiopathies: A retrospective analysis from Eastern Anatolia
by: Emine Hidayet, et al.
Published: (2022-06-01)

Impact of the Recipient’s Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation
by: Alexander Nikoloudis, et al.
Published: (2023-07-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation
by: Zhipeng Li, et al.
Published: (2024-04-01)

The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma
by: Nadira Duraković, et al.
Published: (2021-07-01)

Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation
by: Xun-Hong Cao, et al.
Published: (2024-03-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors
by: B. Linder Grønvold, et al.
Published: (2024-02-01)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
by: Yin Liu, et al.
Published: (2022-11-01)

The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: A historical overview.
by: Margherita Boieri, et al.
Published: (2016-08-01)

Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges
by: Balaji Balakrishnan, et al.
Published: (2023-02-01)

The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
by: Xiaoli Chen, et al.
Published: (2021-09-01)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
by: Christos Demosthenous, et al.
Published: (2021-05-01)

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
by: Pierre Peterlin, et al.
Published: (2023-11-01)

Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation
by: Qingqing Fan, et al.
Published: (2023-12-01)

Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation
by: Sebastian Schlaweck, et al.
Published: (2022-01-01)

Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report
by: Nan Su, et al.
Published: (2022-09-01)

Low pre-transplant levels of mannose-binding lectin are associated with viral infections and mortality after haematopoietic allogeneic stem cell transplantation
by: M. Puente, et al.
Published: (2019-11-01)

Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter
by: Sławomir Milczarek, et al.
Published: (2023-02-01)

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
by: Zhen Li, et al.
Published: (2023-07-01)

Longitudinal Changes of Ocular Surface Microbiome in Patients Undergoing Hemopoietic Stem Cell Transplant (HSCT)
by: Suzanne Clougher, et al.
Published: (2023-12-01)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
by: Shabnam Shokouhi, et al.
Published: (2015-09-01)

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
by: Ariadna Bartoló-Ibars, et al.
Published: (2021-09-01)

Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome
by: Hiroki Hosoi, et al.
Published: (2018-09-01)

Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation
by: Chiara Bini, et al.
Published: (2022-10-01)

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
by: Chenchen Zhao, et al.
Published: (2022-05-01)

High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
by: Zhang G, et al.
Published: (2019-04-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)